Indication
Hidradenitis Suppurativa
67 clinical trials
63 products
2 drugs
Product
BimekizumabClinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2022-04-07
Clinical trial
A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2021-01-14
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-07-07
Product
PlaceboProduct
AvacopanProduct
BDB-001Clinical trial
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-10-19
Product
Vehicle creamProduct
RuxolitinibProduct
ATI-450Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe HSStatus: Completed, Estimated PCD: 2022-12-23
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY® Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2024-10-17
Product
SAR442970Product
ROCEPHINClinical trial
A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients Versus Tetracycline DerivativeStatus: Not yet recruiting, Estimated PCD: 2025-12-15
Product
LymecyclinClinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyStatus: Recruiting, Estimated PCD: 2025-11-24
Clinical trial
Lunsayil LTE: An Extension Trial Assessing Long-term Spesolimab Treatment in Patients With Hidradenitis Suppurativa (HS)Status: Recruiting, Estimated PCD: 2030-04-17
Product
UpadacitinibClinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of AT193 in the Treatment of Patients With Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-03-15
Product
AT193Product
SpesolimabClinical trial
An Open-label, Long-term Extension Trial of Spesolimab Treatment in Adult Patients With Hidradenitis Suppurativa (HS)Status: Completed, Estimated PCD: 2024-04-26
Product
SAR444656Clinical trial
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2025-02-13
Product
TIRZEPATIDEClinical trial
An Open-label Single Center Study to Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe Hidradenitis SuppurativaStatus: Not yet recruiting, Estimated PCD: 2025-03-11
Product
IzokibepClinical trial
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-08-02
Product
SBT777101Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects With Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Randomised, Double-blind, Placebo-controlled, Phase IIb/Phase III Study to Evaluate the Efficacy and Safety of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa. Lunsayil 1.Status: Recruiting, Estimated PCD: 2024-09-04
Product
EltrekibartClinical trial
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy: Amended Protocol to Include a Lutikizumab Open-Label Sub-study in Subjects Naïve to Biologic TherapyStatus: Recruiting, Estimated PCD: 2026-01-24
Product
LutikizumabClinical trial
A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE).Status: Completed, Estimated PCD: 2021-10-01
Product
secukinumabClinical trial
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Active (not recruiting), Estimated PCD: 2026-07-28
Product
RIST4721Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis SuppurativaStatus: Terminated, Estimated PCD: 2023-02-28
Clinical trial
A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2019-04-22
Clinical trial
A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2019-08-13
Product
AVT02Clinical trial
A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)Status: Completed, Estimated PCD: 2021-09-23
Product
KT-474/PlaceboProduct
KT-474Product
SecukinumabClinical trial
A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar PustulosisStatus: Completed, Estimated PCD: 2022-10-04
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CAIN457M2002M to Provide Access to Secukinumab for Adult Patients With Hidradenitis Suppurativa (HS)Status:
Product
LY3041658Clinical trial
A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)Status: Completed, Estimated PCD: 2022-10-20
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2022-03-15
Product
LT-002-158Clinical trial
A Phase 1，Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered LT-002-158 Intended for the Treatment of Skind Disorder in Healthy Adult VolunteersStatus: Not yet recruiting, Estimated PCD: 2024-11-10
Clinical trial
A Multicenter, Open-label, Phase II Study to Explore Efficacy and Safety of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-08-22
Clinical trial
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.Status: Recruiting, Estimated PCD: 2024-09-18
Product
INCB054707Product
ImsidolimabClinical trial
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2022-07-15
Clinical trial
A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial With a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2023-12-01
Product
PTM-001Clinical trial
A Phase 2a/2b, Multicenter, Randomized, Placebo and Active Comparator-controlled, Double-Blind, Dose-ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Terminated, Estimated PCD: 2022-10-14
Product
AdalimumabProduct
BermekimabClinical trial
A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVAStatus: Completed, Estimated PCD: 2022-01-10
Product
PF-06700841Product
PF-06826647Product
PF-06650833Clinical trial
Randomized, Double-blind, Placebo-controlled, Study of Spesolimab in Patients With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2022-01-19
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2021-12-15
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2020-05-19
Product
placeboClinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2021-11-09
Clinical trial
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2021-04-22
Product
bermekimabClinical trial
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis SuppurativaStatus: Terminated, Estimated PCD: 2022-10-12
Product
Intralesional TriamcinoloneClinical trial
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2026-12-26
Product
PovorcitinibClinical trial
A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2024-11-22
Product
CFZ533Product
LYS006Product
MAS825Clinical trial
Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down SyndromeStatus: Recruiting, Estimated PCD: 2024-08-01
Product
TofacitinibClinical trial
Study of the Immunomodulation of the Immune Response in Hidradenitis Suppurativa and in Vitro and ex Vivo Evaluation of a New Therapeutic Strategy (IMOHS)Status: Not yet recruiting, Estimated PCD: 2025-06-30
Product
Blood testsProduct
LOU064Product
VAY736Clinical trial
Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-03-30
Product
Infliximab-dyybClinical trial
Rediscovery of Metformin for the Chronic Disabling Auto-inflammatory Disease Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-01-29
Drug
MetforminClinical trial
An Open-label Parallel Group Pilot Study to Demonstrate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis SuppurativaStatus: Not yet recruiting, Estimated PCD: 2025-09-30
Product
SiplizumabClinical trial
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-05-09
Product
SonelokimabClinical trial
Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trialStatus: Completed, Estimated PCD: 2021-12-30
Product
GuselkumabClinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2025-06-17
Clinical trial
Capsule Microbiota Transplant Therapy for Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2024-10-01
Product
Fecal MicrobiotaClinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2025-06-17
Drug
VarlilumabClinical trial
A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica)Status: Completed, Estimated PCD: 2014-01-01
Product
UstekinumabClinical trial
A Pilot Study Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo in the Treatment of Moderate-to-severe Hidradenitis Suppurativa (HS).Status: Recruiting, Estimated PCD: 2025-12-31
Product
DeucravacitinibClinical trial
A Prospective Open-label Trial Examining the Efficacy and Safety of Anifrolumab for Hidradenitis Suppurativa (HS)Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
AnifrolumabClinical trial
A Multicenter Phase I/II Clinical Trial, Randomized, Double Blind, Controlled With Placebo to Evaluate Safety and Efficiency of Allogenic Adult Mesenchymal Stem Cells From Adipose Tissue in the Treatment of Draining Fistulas in Patients With Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2025-10-26
Clinical trial
Botulinum Toxin-A for Hidradenitis SuppurativaStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Product
Botulinum toxin type AClinical trial
Effects of Gentian Violet Treatment on Patients With Hidradenitis SuppurativaStatus: Not yet recruiting, Estimated PCD: 2024-10-01
Product
Gentian VioletClinical trial
The Efficacy of Laser Hair Removal Therapy in Patients With Mild to Moderate HS, a Randomized Controlled Trial.Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
ClindamycinClinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2025-03-11
Clinical trial
An Investigator Initiated, Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study to Assess the Safety and Efficacy of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2022-08-29
Product
RGRN-305Clinical trial
An Exploratory, Proof-of-Concept Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-01-13
Product
FostamatinibClinical trial
Prospective Case Series on a Combination Methylene Blue, Gentian Violet, and Ovine Forestomach-derived Extracellular Matrix Dressing for Hidradenitis SuppurativaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2025-03-11
Clinical trial
Targeting Nociceptors in Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2028-04-30
Product
Botulinum toxinClinical trial
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Not yet recruiting, Estimated PCD: 2026-12-14